** Shares of Orthocell OCC.AX rise 8.1% to A$1.27, snap a four-day losing streak
** Stock set for its strongest session since April 10, if gains hold
** The biotech firm announces appointment of its first four U.S. distributors of its flagship nerve repair product Remplir
** Co says it is targeting to appoint about 10 U.S. distributors by June-end which would account for representation in around 25 states in the U.S.
** Stock down 7% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.